ASCO Annual Meeting

Promising responses rates were seen with larotrectinib, a highly selective, central nervous system-active TRK inhibitor, in patients with TRK fusion cancer, including in those with CNS metastases at baseline.

In an update of the ARROW trial, pralsetinib was well tolerated and demonstrated robust and durable anti-tumor activity in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

Niraparib has an acceptable safety profile for patients with platinum-sensitive recurrent ovarian cancer, regardless of the dose being adjusted for weight, according to updated results from the phase 3 NORMA trial.

Based on 7-year follow-up data, the use of front-line ibrutinib monotherapy has sustained progression-free survival and overall survival benefit compared with chlorambucil as treatment of patients with chronic lymphocytic leukemia.

The novel agent, zenocutuzumab demonstrated promise as treatment of patients with NRG1 fusion–positive cancers, in the phase 1/2 eNRGy study.

New data from the phase 2 SPEARHEAD-1 trial showed that afami-cel can elicit encouraging responses in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Allogeneic hematopoietic cell transplantation was shown to be safe when performed with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma

A robust and durable response was seen in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia after receiving a single infusion of KTE-X19, a CAR T-cell therapy.

Jorge Nieva, MD, discusses the backgroup to the IMpower010 study, the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.

Data from the ongoing escalation and expansion trial CTNO1552101 showed promising results for the use of TN0155 in adults with advanced solid tumors.

Amivantamab in combination with lazertinib led to responses in more than a third of patients with EGFR-mutant non–small cell lung cancer who had progressed on treatment with osimertinib but had not received chemotherapy.

Continued efficacy is seen with nivolumab and ipilimumab plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer.

Across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone.

Median duration of response was doubled with tivozanib compared with sorafenib in patients with metastatic renal cell carcinoma.

After 4 years of treatment with the combination of nivolumab and ipilimumab, the therapy showed durable, long-term overall survival benefit compared with chemotherapy in patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Mobocertinib, elicited rapid, deep, and durable responses and demonstrated a tolerable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in a phase 1/2 study.

In a pharmacokinetic analysis of the first 15 patients in the phase 2 TBCRC049 study, researchers saw the first evidence for concentrations of tucatinib and ONT-993 in the cerebral spinal fluid of patients with HER2+ metastatic breast cancer with newly diagnosed leptomeningeal metastasis.

In patients with metastatic castration-resistant prostate cancer treated in a phase 1/2a study, the HPN424, a tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager was well tolerated and demonstrated antitumor activity.

One infusion of ciltacabtagene autoleucel lead to early and deep responses in a cohort of patients previously treated for relapsed/refractory multiple myeloma, according to findings the phase 2 CARTITUDE-2 study.

Pembrolizumab plus concurrent chemoradiation therapy continues to demonstrate promising antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

Men with nonmetastatic castration-resistant prostate cancer tolerated treatment with darolutamide well, according to findings from the phase 3 ARAMIS trial.

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.

Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.

In patients with ovarian cancer and BRCA mutations who were enrolled in 3 different trials, maintenance treatment with niraparib improved progression-free survival compared with placebo with no new safety signals.

lenvatinib plus pembrolizumab elicited a response in some patients with advanced colorectal cancer.

In women with locally advanced cervical cancer, administering adjuvant chemotherapy following standard cisplatin-based chemoradiation did not improve survival outcomes, according to findings from the phase 3 OUTBACK trial.

Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.

Compared to chemotherapy alone, the addition of the immunotherapy agent toripalimab to gemcitabine plus cisplatin significantly improved progression-free survival in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.

LuPSMA added to standard of care led to a nearly 40% reduction in the risk of death versus standard of care alone in the phase 3 VISION study.